| Symbol | ICCM |
|---|---|
| Name | ICECURE MEDICAL LTD. |
| Sector | HEALTH CARE |
| Region | Middle East |
| Industry | Medical/Dental Instruments |
| Address | 7 HAESHEL STREET,SOUTHERN INDUSTRIAL PARK, CAESAREA, 3079504, Israel |
| Telephone | +972 46230333 |
| Fax | — |
| — | |
| Website | https://www.icecure-medical.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001584371 |
| Description | Icecure Medical Ltd is a commercial-stage medical device company. The company is engaged in the research, development, and marketing of cryoablation systems and technologies based on liquid nitrogen, or LN2, for treating tumors. Its cryoablation technology is a minimally invasive alternative to surgical intervention, for tumors, including those found in the breast, lungs, kidneys, bones, and other indications. Additional info from NASDAQ: |
IceCure Highlights Two New Peer-Reviewed Publications Supporting Cryoablation in Breast Cancer Treatment De-Escalation
Read moreIceCure Highlights Two New Peer-Reviewed Publications Supporting Cryoablation in Breast Cancer Treatment De-Escalation
Read moreIceCure Reports its Financial Results for the First Half of 2026 with 45% Revenue Growth Year-Over-Year
Read moreIceCure Reports its Financial Results for the First Half of 2026 with 45% Revenue Growth Year-Over-Year
Read moreIceCure Medical Adds Adventist Health as U.S. Clinical Site for its Post-Marketing "ChoICE" Study for Low-Risk Breast Cancer Cryoablation Treatment
Read moreIceCure Medical Adds Adventist Health as U.S. Clinical Site for its Post-Marketing "ChoICE" Study for Low-Risk Breast Cancer Cryoablation Treatment
Read moreIceCure Medical to Report First Half 2026 Financial and Operating Results on August 12, 2026
Read moreIceCure Medical to Report First Half 2026 Financial and Operating Results on August 12, 2026
Read moreIceCure: SIO Petitions NCCN to Include Cryoablation in Breast Cancer Treatment Guidelines, Citing IceCures FDA Clearance ofProSense®
Read moreIceCure Medical Kicks Off its Post-Marketing "ChoICE" Study for the Low-Risk Breast Cancer Treatment at First U.S Clinical Site
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT07629206 | Post-Marketing Study for Early-Stage Low-Risk Breast Cancer Treatment Using Pro… | Na | Low-Risk, Early Stage Breast Cancer | Active_Not_Recruiting | 2026-07-17 | 2034-09-01 | ClinicalTrials.gov |
| NCT06300125 | Percutaneous Cryoablation of Low-risk Early Breast Cancer | — | Breast Cancer | Recruiting | 2024-04-15 | 2031-03-01 | ClinicalTrials.gov |
| NCT02200705 | Cryoablation of Low Risk Small Breast Cancer- ICE3 Trial | Na | Breast Cancer | Completed | 2014-10-01 | 2024-05-26 | ClinicalTrials.gov |
| NCT02399124 | Post Marketing Surveillance for PROSENSE™ a Cryotherapy Treatment of Renal Cell… | Na | Renal Cell Carcinoma | Active_Not_Recruiting | 2014-07-01 | 2026-03-01 | ClinicalTrials.gov |
| NCT01735812 | Laparoscopic Cryoablation of Uterine Fibroids | Na | Symptomatic Uterine Fibroids | Withdrawn | 2012-12-01 | 2015-12-01 | ClinicalTrials.gov |
| NCT01671943 | Cryotherapy for Breast Cancer Trial | Na | Breast Carcinoma | Completed | 2012-08-01 | 2014-07-01 | ClinicalTrials.gov |
| NCT00910312 | ICE-SENSE™ Cryotherapy for Breast Fibroadenoma Trial | Na | Fibroadenoma | Completed | 2009-04-01 | 2013-01-01 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Cryoablation | Other | Approved | Low-Risk, Early Stage Breast Cancer | ACTIVE_NOT_RECRUITING | NCT07629206 |
| Ice-Sense3TM/ ProSenseTM | Other | Approved | Breast Cancer | COMPLETED | NCT02200705 |
| Cryoablation | Other | Approved | Low-Risk, Early Stage Breast Cancer | NOT_YET_RECRUITING | NCT07629206 |
| Ice-Sense3TM | Other | Approved | Breast Carcinoma | COMPLETED | NCT01671943 |
| IceSense3 system | Other | Approved | Symptomatic Uterine Fibroids | WITHDRAWN | NCT01735812 |
| Ice-Sense3TM/ ProSenseTM | Other | Approved | Breast Cancer | COMPLETED | NCT02200705 |
| Cryoablation | Other | Preclinical | Breast Cancer | RECRUITING | NCT06300125 |
| PROSENSE™ | Other | Approved | Renal Cell Carcinoma | ACTIVE_NOT_RECRUITING | NCT02399124 |
| Cryoablation | PROCEDURE | Preclinical | Breast Cancer | RECRUITING | NCT06300125 |
| PROSENSE™ | DEVICE | Approved | Renal Cell Carcinoma | ACTIVE_NOT_RECRUITING | NCT02399124 |
| Ice-Sense3TM/ ProSenseTM | DEVICE | Approved | Breast Cancer | COMPLETED | NCT02200705 |
| IceSense3 system | DEVICE | Approved | Symptomatic Uterine Fibroids | WITHDRAWN | NCT01735812 |
| Ice-Sense3TM | DEVICE | Approved | Breast Carcinoma | COMPLETED | NCT01671943 |
| Ice-Sense | DEVICE | Approved | Fibroadenoma | COMPLETED | NCT00910312 |